Longevity & AgingNew Drug Daraxonrasib Doubles Pancreatic Cancer Survival in Landmark Trial
Pancreatic cancer has a five-year survival rate of just 13%, and progress has been frustratingly slow for decades. At the 2026 ASCO oncology conference, results from a trial of daraxonrasib — a drug targeting the KRAS mutation found in most pancreatic cancers — reportedly doubled survival rates, earning a rare standing ovation from the medical community. KRAS was once considered 'undruggable,' but researchers discovered a hidden binding pocket on the protein, leading to a new class of inhibitors. Earlier approvals of sotorasib and adagrasib for lung cancer paved the way. Daraxonrasib appears to be the most potent yet, with trials now expanding to lung cancer and combination therapies. This represents a potential turning point in treating some of the most lethal cancers.
